Pembrolizumab vs Yttrium Y 90 Ibritumomab Tiuxetan

## Pembrolizumab vs Yttrium Y 90 Ibritumomab Tiuxetan: Overview

This comparison examines the pharmacological differences between **Pembrolizumab** and **Yttrium Y 90 Ibritumomab Tiuxetan**.

## Mechanism of Action

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Pembrolizumab — 26 days; Yttrium Y 90 Ibritumomab Tiuxetan — N/A.

## Chemical Properties

**Type**: Pembrolizumab — Antibody; Yttrium Y 90 Ibritumomab Tiuxetan — Antibody.